Incyte Corporation

NasdaqGS:INCY Lagerbericht

Marktkapitalisierung: US$19.5b

Incyte Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Der Umsatz und der Gewinn von Incyte werden voraussichtlich um 2.1% bzw. 15.6% pro Jahr zurückgehen. Der Gewinn je Aktie wird voraussichtlich um 16.8% pro Jahr sinken. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.3% betragen.

Wichtige Informationen

-15.6%

Wachstumsrate der Gewinne

-16.85%

EPS-Wachstumsrate

Biotechs Gewinnwachstum25.2%
Wachstumsrate der Einnahmen-2.1%
Zukünftige Eigenkapitalrendite17.28%
Analystenabdeckung

Good

Zuletzt aktualisiert12 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Analyseartikel • Oct 31

Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Incyte Corporation ( NASDAQ:INCY ) defied analyst predictions to release its quarterly results, which were ahead of...

Recent updates

Analyseartikel • May 10

Impressive Earnings May Not Tell The Whole Story For Incyte (NASDAQ:INCY)

Incyte Corporation ( NASDAQ:INCY ) announced strong profits, but the stock was stagnant. We did some digging, and we...
Narrativ-Update • May 03

INCY: Future Returns Will Depend On Managing Patent Cliff And Pipeline Execution

Incyte's updated analyst price target has moved from $100.10 to $108.50, reflecting how analysts are weighing a series of recent target hikes from firms such as Oppenheimer, BofA, RBC, Barclays, Morgan Stanley, Piper Sandler and H.C. Wainwright, against more cautious views from UBS and Jefferies focused on patent and long term growth uncertainties. Analyst Commentary Recent research highlights a clear split in how analysts view Incyte, with several firms lifting price targets or initiating with a positive stance, while others focus on patent risk and long term growth questions.
Seeking Alpha • May 01

Incyte: Strong Business, But Risks Remain

Summary Incyte is rated a hold due to strong fundamentals but high revenue concentration in Jakafi ahead of its 2028 patent cliff. INCY trades at 13x P/E, below its historical premium, despite 60% stock appreciation and robust 21% YoY revenue growth. Management guides 2026 net sales at roughly $4.8B, with Jakafi still expected to represent most of the total. Potential launches in 2026 and 2027, including Jakafi XR and povorcitinib, could improve the story. Read the full article on Seeking Alpha
Narrativ-Update • Apr 18

INCY: Jakafi 2028 Patent Cliff Will Pressure Reliance On Long Dated Pipeline

The analyst price target for Incyte has shifted to reflect a modest fair value increase of about $2, as analysts weigh patent cliff concerns around Jakafi in 2028 against longer term pipeline opportunities and a higher assumed future P/E multiple. Analyst Commentary Recent research has highlighted a split view on Incyte, with some firms lifting price targets while others have taken a more cautious stance.
Narrativ-Update • Apr 04

INCY: Late Stage Pipeline And 2026 Readouts Will Offset Patent Cliff Risk

Analysts have modestly adjusted their price targets on Incyte, with recent cuts of up to $10 alongside several incremental increases. This reflects a balance between concerns around Jakafi's 2028 patent cliff and confidence in longer term revenue drivers that are considered harder to underwrite today.
Narrativ-Update • Mar 21

INCY: Late Stage Pipeline And 2026 Milestones Will Offset Patent Cliff Risk

Analysts' price targets for Incyte have shifted, with one firm cutting its view from $120 to $94 on patent cliff concerns, while others have nudged targets higher into the $90 to $128 range. This reflects a balance between Jakafi loss of exclusivity risk and longer term pipeline potential.
Narrativ-Update • Mar 07

INCY: Late Stage Pipeline Progress And 2026 Readouts Will Reshape Earnings Power

Incyte's updated analyst price target has nudged higher, with several firms lifting their views into a roughly $117 to $128 range as analysts highlight a clearer revenue roadmap, upcoming Phase 3 catalysts, and a more constructive sector backdrop, despite at least one downgrade on near term catalysts. Analyst Commentary Recent Street research around Incyte has tilted constructive, with several bullish analysts revisiting their models and lifting price targets as they get more confidence in the company’s roadmap and execution plans.
Narrativ-Update • Feb 21

INCY: Late Stage Pipeline Execution Will Reshape Earnings Power Beyond Jakafi

The analyst fair value estimate for Incyte has been raised by $6 to $135. This change reflects recent price target increases across several firms as analysts point to a fuller pipeline, higher assumed revenue growth, a higher future P/E multiple, and offsetting adjustments to discount rate and profit margin assumptions.
Narrativ-Update • Feb 06

INCY: Late Stage Pipeline Reliance Will Face Pressure As Near Term Catalysts Remain Scarce

Analysts have lifted their price targets on Incyte by as much as US$27, citing a fuller late stage pipeline, new coverage with bullish views, and updated assumptions around discount rates, revenue growth, profit margins, and forward P/E that support a higher valuation range. Analyst Commentary Recent research on Incyte has tilted more constructive on potential upside, but there are also clear points of caution that investors should keep in mind when thinking about valuation and execution risk.
Narrativ-Update • Jan 23

INCY: Late Stage Pipeline Execution Will Face Scrutiny As Near Term Catalysts Thin

Narrative Update: Incyte (INCY) The updated analyst price target for Incyte moves from $60 to $70, reflecting analysts' incorporation of higher projected profit margins, a lower future P/E, and recent price target raises that highlight a fuller late stage pipeline and upcoming clinical readouts, even as some research points to fewer near term catalysts. Analyst Commentary Recent Street commentary on Incyte mixes higher price targets with tempered expectations around the pace and reliability of execution.
Narrativ-Update • Jan 09

INCY: Pipeline Progress And Policy Tailwinds Will Reshape Earnings Power

Analysts have lifted their fair value estimate for Incyte to $129 from $92, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E following recent Street research, including the higher $90 price target cited by Goldman Sachs. Analyst Commentary Recent Street research has added a more constructive tone around Incyte, with bullish analysts pointing to updated assumptions on risk, growth, and profitability to support higher valuation frameworks.
Narrativ-Update • Dec 25

INCY: Future Returns Will Hinge On Executing High-Expectation Pipeline Under New Leadership

Analysts have nudged their price target on Incyte slightly higher, to $82 from $81. This reflects a modestly improved fair value estimate even as they caution that the recent share rally has largely priced in high expectations for key pipeline assets and new management.
Narrativ-Update • Dec 11

INCY: Future Returns Will Depend On Delivering High-Risk Hematology Pipeline Milestones

Analysts have nudged their fair value estimate for Incyte higher, lifting the implied price target by about $4 per share to roughly $100. They are balancing moderate upward revisions to growth assumptions and valuation multiples against a view that recent gains already reflect high expectations for key pipeline assets and Opzelura expansion.
Narrativ-Update • Nov 27

INCY: Share Momentum Will Slow As R&D Execution Risks Remain Elevated

Incyte's analyst price target has increased modestly to $95.57 from $93.82. Analysts cite continued pipeline momentum, recent regulatory approvals, and new leadership as key drivers supporting higher valuation expectations.
Narrativ-Update • Nov 12

INCY: Share Momentum Will Stall As Execution Risks Come Into Focus

Incyte's analyst price target has increased from $86.86 to $93.82, as analysts cite improving profit margins, strong product pipeline updates, and enhanced growth visibility following recent regulatory and clinical developments. Analyst Commentary Recent analyst research on Incyte reflects a range of perspectives on the company's valuation, growth potential, and commercial execution.
Analyseartikel • Oct 31

Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Incyte Corporation ( NASDAQ:INCY ) defied analyst predictions to release its quarterly results, which were ahead of...
Narrativ-Update • Oct 29

Upcoming Clinical Data And New Management Will Shape Future Performance

Incyte's analyst fair value price target has been raised by nearly $2 to approximately $87, as analysts point to recent clinical updates and pipeline progress strengthening the company's growth outlook. Analyst Commentary Recent Street research on Incyte reflects a mix of optimism regarding the company's growth drivers and caution about valuation and future risks.
Narrativ-Update • Oct 15

Pipeline And Precision Medicine Will Transform Global Immunotherapy Landscape

Incyte's analyst price target has increased slightly from $83.62 to $84.76, as analysts cite ongoing commercial momentum and incremental advances in the company's growth drivers. Analyst Commentary Recent analyst activity reflects a range of perspectives on Incyte’s outlook, with notable adjustments to ratings and price targets based on pipeline progress, commercial momentum, and valuation concerns.
Narrativ-Update • Sep 26

Pipeline And Precision Medicine Will Transform Global Immunotherapy Landscape

Increased analyst confidence in Incyte’s pipeline progress, strong Opzelura execution, and management’s ability to offset Jakafi’s patent expiry has driven the consensus price target up from $81.55 to $83.62. Analyst Commentary Bullish analysts highlight increased visibility and incremental growth from FDA approval of Opzelura for pediatric atopic dermatitis, along with strong commercial execution under new leadership.
Narrativ-Update • Sep 11

Pipeline And Precision Medicine Will Transform Global Immunotherapy Landscape

Analysts have modestly raised Incyte’s price target to $81.55, citing strengthened leadership, increased confidence in commercial execution, and upcoming pivotal data readouts—though concerns about Jakafi’s patent expiry remain a key overhang. Analyst Commentary Bullish analysts cite increased confidence in Incyte's commercial execution, multiple promising pipeline assets ("shots on goal"), and strengthened leadership, particularly following meetings with new CEO Bill Meury and Head of R&D.
Analyseartikel • Aug 14

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

NasdaqGS:INCY 1 Year Share Price vs Fair Value Explore Incyte's Fair Values from the Community and select yours Despite...
Narrativ-Update • Aug 07

Pipeline And Precision Medicine Will Transform Global Immunotherapy Landscape

With both Incyte’s future P/E and revenue growth forecasts holding steady, analysts maintained their price target at $80.83. What's in the News FDA approved Monjuvi (tafasitamab-cxix) with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, showing significant improvement in progression-free survival.
Analyseartikel • Aug 06

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Incyte Corporation's ( NASDAQ:INCY ) stock was strong after they recently reported robust earnings. However, we think...
Seeking Alpha • Mar 18

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib

Summary Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is expected to be worth $1.57 billion by 2031; Incyte can do well in biologic experienced HS patients. Regulatory discussions possible of expanded approval of OPZELURA for Prurigo Nodularis patients; However, regulatory discussion will be needed to determine if one phase 3 study will be enough for filing. Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, a 15% YoY increase, driven by JAKAFI and OPZELURA. Read the full article on Seeking Alpha
Seeking Alpha • Feb 11

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Summary Incyte's Q4 2024 earnings showed mixed results with slight revenue beat but missed non-GAAP earnings estimates.  The stock has declined due to 2025 guidance coming below expectations. Despite slowing sales growth for Jakafi and Opzelura, Incyte's pipeline with four product launches in 2025 and potential $1B incremental revenue by 2029 bodes well for continued growth. The company has a strong track record of revenue growth and a robust pipeline targeting over 10 high-impact product launches by 2030. I maintain a STRONG BUY rating for Incyte with a 12-month price target of $94/share, representing a 34% upside potential. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:INCY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20286,4841,6801,6211,75318
12/31/20276,2291,5981,4681,95821
12/31/20265,6221,3771,3251,72921
3/31/20265,3611,4321,4211,517N/A
12/31/20255,1411,2871,3301,413N/A
9/30/20254,8131,1891,1721,251N/A
6/30/20254,5858719461,003N/A
3/31/20254,41321289383N/A
12/31/20244,24133235335N/A
9/30/20244,0763217102N/A
6/30/20243,85797-140-61N/A
3/31/20243,768745791821N/A
12/31/20233,696598449496N/A
9/30/20233,609425566632N/A
6/30/20233,513366698781N/A
3/31/20233,470324561649N/A
12/31/20223,395341892970N/A
9/30/20223,331876711802N/A
6/30/20223,320945665760N/A
3/31/20223,115933609759N/A
12/31/20212,986949568749N/A
9/30/20212,913535543741N/A
6/30/20212,721338450668N/A
3/31/20212,703478569765N/A
12/31/20202,667-296-312-125N/A
9/30/20202,457-335-266-100N/A
6/30/20202,388-191-108-12N/A
3/31/20202,229-376-227-128N/A
12/31/20192,159447N/A711N/A
9/30/20192,108405N/A663N/A
6/30/20192,006306N/A592N/A
3/31/20191,997253N/A471N/A
12/31/20181,882109N/A336N/A
9/30/20181,798-109N/A163N/A
6/30/20181,729-102N/A17N/A
3/31/20181,534-167N/A101N/A
12/31/20171,536-313N/A-93N/A
9/30/20171,419-155N/A91N/A
6/30/20171,306-154N/A133N/A
3/31/20171,226-107N/A34N/A
12/31/20161,106104N/A305N/A
9/30/20161,023151N/A280N/A
6/30/201694174N/A193N/A
3/31/201685849N/A189N/A
12/31/20157547N/A89N/A
9/30/2015634-86N/A61N/A
6/30/201564413N/A81N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: INCYFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-15.6% pro Jahr).

Ertrag vs. Markt: INCYFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-15.6% pro Jahr).

Hohe Wachstumserträge: INCYFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: INCYDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-2.1% pro Jahr).

Hohe Wachstumseinnahmen: INCYDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-2.1% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: INCYDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.3%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/15 13:14
Aktienkurs zum Tagesende2026/05/15 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Incyte Corporation wird von 44 Analysten beobachtet. 21 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jasper HellwegArgus Research Company
Thomas RussoBaird
Peter LawsonBarclays